Dr. Joseph Lawen retiring after 33 years at Nova Scotia Health and performing over 2000 kidney transplant surgeries and 500 living donor transplants | Nova Scotia Health Authority https://t.co/pxK4sOJII3
#CUASF proudly supports a mentorship program to highlight the collaboration between mentor & mentee with the winners of the Early Investigator Research Scholarship. @_TomSkinner
https://t.co/kVlxIlbx9j
Colleagues: can we please stop overstating the risk of
1. postop NSAIDs
2. Contrast nephropathy
3. Nephrotenic systemic fibrosis.
Toradol, CT contrast and gadolinium can all be used in patients with CKD.
🚺, with 3 children of her own, comes forward to donate a kidney to her friend’s child. Child gets kidney from someone else. She still donates her kidney … anonymously … to a stranger. The altruism in some is just awesome #BeADonor@UHNTransplant@TrilliumGift
Significant disparities in access to preemptive repeat kidney transplant persist despite patients with a prior transplant having more exposure and existing knowledge of the transplant process.
Honored to contribute to the NEW 2021 CKD-EPI #race-free #eGFR equation in our latest research published in @NEJM today. I learned a ton about equations. Importantly, the main lesson is that #race should NOT be incorporated into #biological tools. https://t.co/RvfWWwGOox
NEW Research—Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic #renalcellcarcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial https://t.co/tToQW8CddL
@martinurology@RRGonzalezMD@DrDeanElterman@Dr_KevinZorn We published in @CanUrolAssoc journal a cost comparison of new TUR platforms in a Canadian hospital. With shorter hospital stay, no doubt TUVP is cheaper than monopolar overall, but Canadian hospital beds are full regardless of outpatient surgery. https://t.co/2eiQ8z6xpQ
Shocking statistics! Stapler mis-fires are an ever-present fear of any #mis surgeon.
But will this fix the issues with Premarket Notification (new devices approved based on similarity to previously approved iterations)?